All In MedTech

FDA Clearance Tracker · P900030-S009

CONTIGEN BARD COLLAGEN IMPLANT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 21, 2006 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 21, 2006

Approved

Time to decision

465 days

Received Jun 13, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P900030-S009
Device name
CONTIGEN BARD COLLAGEN IMPLANT
Applicant location
Goleta, CA
Received
Jun 13, 2005
Decided
Sep 21, 2006
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P900030

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR REVISED DIRECTIONS FOR USE (DFU) THAT INCLUDE INFORMATION FROM THE POST-APPROVAL STUDY ON COHORT B.

Source documents

Other decisions for Allergan, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.